Journal of Nippon Medical School: Vol.66 No.1 page.033

Journal of Nippon Medical School

Select Language
in Japanese < > in English

Full Text of this Article

in English PDF (132k)

ArticleTitle Chromosome 8 copy numbers and the c-myc gene amplification in non-small cell lung cancer Analysis by interphase cytogenetics

AuthorList Hirotoshi Kubokura¹⁾, Kiyoshi Koizumi ¹⁾, Mitsunobu Yamamoto ²⁾, Shigeo Tanaka ¹⁾

Affiliation ¹⁾ The Department of Surgery Second, Nippon Medical School ²⁾ The Department of Thoracic Surgery, Saitama Cancer Center

Language EN

Volume 66

Issue 2

Year 1999

Page 107-112

Received November 24, 1998

Accepted December 24, 1998

Keywords non-small cell lung cancer, dual color FISH, chromosome 8 copy number, the c-myc gene amplification

Abstract Amplification of the c-myc gene has been reported in non-small cell lung cancer (NSCLC). We performed dual color fluorescence in situ hybridization (FISH) to detect amplifications of the c-myc gene on chromosome 8 to evaluate the relationship between these possible abnormalities and pathological stage. Tumor tissue samples were obtained from 29 patients of NSCLC in Stage I (n=15) and III (n=14) who underwent lobectomy at Saitama Cancer Center. Samples were analyzed for chromosome 8 centromere and c-myc gene by dual color FISH. The numerical aberration rate of chromosome 8 was 36.8±20.3% in Stage I and 40.6±24.8% in Stage III. The amplification rate of c-myc gene was 48.3±15.2% in Stage I and 57.4±17.0% in Stage III. There was a significant difference in the numerical aberration rate of chromosome 8 between patients who survived for 5 years or more (28.8±17.5%) and those who survived less than 5 years (44.7±23.1%). The amplification rate of c-myc gene was not different between patients who survived more and less than 5 years survival, and who survived more and less than 3 years. The 5 year-survival rate in patients who showed 40% or more of chromosome 8 aberrations (n=13) was 15.4%, which revealed significantly less than that of patients who showed less than 40% of aberrations (n=16)(56.3%). There was no difference between the 5 year-survival rate in patients whose amplification rates of c-myc gene were equal or more than 50% (n=16) and less than 50% (n=13)(25.0% and 53.9%). The rate of chromosome 8 aberrations and the c-myc gene amplification rate were not correlated with pathological stage. However, the rate of chromosome 8 aberration showed correlation in terms of longevity of survival rate, therefore we considered the rate of chromosome 8 aberration to be an additional prognostic factor of patient with NSCLC.

Correspondence to Hirotoshi Kubokura, The Department of Surgery Second, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan

ArticleTitle	Chromosome 8 copy numbers and the c-myc gene amplification in non-small cell lung cancer Analysis by interphase cytogenetics
AuthorList	Hirotoshi Kubokura¹⁾, Kiyoshi Koizumi ¹⁾, Mitsunobu Yamamoto ²⁾, Shigeo Tanaka ¹⁾
Affiliation	¹⁾ The Department of Surgery Second, Nippon Medical School ²⁾ The Department of Thoracic Surgery, Saitama Cancer Center
Language	EN
Volume	66
Issue	2
Year	1999
Page	107-112
Received	November 24, 1998
Accepted	December 24, 1998
Keywords	non-small cell lung cancer, dual color FISH, chromosome 8 copy number, the c-myc gene amplification
Abstract	Amplification of the c-myc gene has been reported in non-small cell lung cancer (NSCLC). We performed dual color fluorescence in situ hybridization (FISH) to detect amplifications of the c-myc gene on chromosome 8 to evaluate the relationship between these possible abnormalities and pathological stage. Tumor tissue samples were obtained from 29 patients of NSCLC in Stage I (n=15) and III (n=14) who underwent lobectomy at Saitama Cancer Center. Samples were analyzed for chromosome 8 centromere and c-myc gene by dual color FISH. The numerical aberration rate of chromosome 8 was 36.8±20.3% in Stage I and 40.6±24.8% in Stage III. The amplification rate of c-myc gene was 48.3±15.2% in Stage I and 57.4±17.0% in Stage III. There was a significant difference in the numerical aberration rate of chromosome 8 between patients who survived for 5 years or more (28.8±17.5%) and those who survived less than 5 years (44.7±23.1%). The amplification rate of c-myc gene was not different between patients who survived more and less than 5 years survival, and who survived more and less than 3 years. The 5 year-survival rate in patients who showed 40% or more of chromosome 8 aberrations (n=13) was 15.4%, which revealed significantly less than that of patients who showed less than 40% of aberrations (n=16)(56.3%). There was no difference between the 5 year-survival rate in patients whose amplification rates of c-myc gene were equal or more than 50% (n=16) and less than 50% (n=13)(25.0% and 53.9%). The rate of chromosome 8 aberrations and the c-myc gene amplification rate were not correlated with pathological stage. However, the rate of chromosome 8 aberration showed correlation in terms of longevity of survival rate, therefore we considered the rate of chromosome 8 aberration to be an additional prognostic factor of patient with NSCLC.
Correspondence to	Hirotoshi Kubokura, The Department of Surgery Second, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan